A clinical study published on September 5, 2026, indicates that psilocybin may effectively prevent debilitating nerve damage caused by common chemotherapy treatments.
Researchers observed that patients receiving controlled doses experienced a 40% reduction in peripheral neuropathy symptoms compared to the control group during the trial.
The medical team is now seeking regulatory approval for larger-scale trials to determine if this treatment can be integrated into standard oncology care protocols.